The Food and Drug Administration recently approved Journavx to treat short-term pain. It’s a new class of non-opioid pain ...

Drugs that target wakefulness, molecules in cannabis and wearable devices that modulate brain activity could help people with ...

Beyond 2027, Idorsia aims to continue the sales trajectory of QUVIVIQ with a stable OPEX, leading to higher sustainable ...